当前价格
$91.38
内在价值
使用下方计算器估算
对 Abbott Laboratories 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Earnings Yield
3.93%
ROE (TTM)
11.4%
基于过去 12 个月的数据，ABT 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
ABT 的过去 12 个月市盈率反映投资者为 Abbott Laboratories 每一美元收益所支付的价格。该指标在与Medical - Devices同类公司和公司自身历史区间对比时最有意义。
ABT 是否被高估取决于将其市盈率与Medical - Devices同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估，但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。
对 Abbott Laboratories 使用 PE 估值的步骤：(1) 将当前市盈率与Medical - Devices中位数对比评估相对定价，(2) 查看 PEG 比率以调整增长预期，(3) 参考 5 年 PE 历史区间判断当前位置，(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。
PEG 比率将市盈率除以预期盈利增速，提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估，高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。
PE 市盈率给出快速的相对定价——ABT 相对于Medical - Devices同类的估值水平。DCF 基于预期自由现金流提供绝对价值。建议用 PE 做快速筛选，用 DCF 做深度分析。两种方法各有盲区：PE 忽略了资本结构和现金流质量，DCF 则对增长率和折现率假设非常敏感。
